GIP receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Temperature dependence: LED performance largely depends on the ambient temperature of the operating environment – or thermal management properties. Overdriving an LED in high ambient temperatures may result in overheating the LED package, eventually leading to device failure. An adequate heat sink is needed to maintain long life. This is especially important in automotive, medical, and military uses where devices must operate over a wide range of temperatures, and require low failure rates.
=== YqjD === YqjD is an inner membrane protein specific to stationary phase. It binds to 70S and 100S ribosomes and has been proposed as of 2018 to mediate the localization (moving) of hibernating ribosomes to the cell membrane. While cells lacking YqjD do not have altered growth rates of ribosome composition, artificially high levels of it quickly halts growth depending on the protein's ribosome-binding capability.
The first ionisation energy of an atom is the energy required to remove an electron from it. This varies with the atomic radius: ionisation energy increases left to right and down to up, because electrons that are closer to the nucleus are held more tightly and are more difficult to remove. Ionisation energy thus is minimized at the first element of each period – hydrogen and the alkali metals – and then generally rises until it reaches the noble gas at the right edge of the period. There are some exceptions to this trend, such as oxygen, where the electron being removed is paired and thus interelectronic repulsion makes it easier to remove than expected. In the transition series, the outer electrons are preferentially lost even though the inner orbitals are filling. For example, in the 3d series, the 4s electrons are lost first even though the 3d orbitals are being filled. The shielding effect of adding an extra 3d electron approximately compensates the rise in nuclear charge, and therefore the ionisation energies stay mostly constant, though there is a small increase especially at the end of each transition series. As metal atoms tend to lose electrons in chemical reactions, ionisation energy is generally correlated with chemical reactivity, although there are other factors involved as well.
Sources: en.wikipedia.org
== Characterization == Designing effective antimicrobial surfaces demands an in-depth understanding of the initial microbe-surface adhesion mechanisms. Scanning electron microscopy (SEM) is used for nonliving samples. Bacterial colony forming unit (CFU) counting requires overnight incubation and detects bacteria that readily grow on solid media. Molecular dynamics (MD) simulation can be used to minimize the number of experiments with engineered substrates, with the quantification of time-lapse fluorescence microscopy images that can be processed in an hour. Contact angle measurements can be used to characterize micro/nano-pillars use for rupturing cell walls. The analysis of the zeta potential by the streaming potential method of either an antimicrobial coating or a self-disinfectant material in contact with an aqueous environment, or by electrophoretic light scattering of nanoparticle dispersions of antibacterial additives reveal information about surface and interfacial charge and let predict the electrostatic attraction or repulsion of microorganisms.
=== ELISA === Enzyme-linked immunosorbent assay (ELISA) uses antigen-coated microtitre plates for the detection of ANAs. Each well of a microtitre plate is coated with either a single antigen or multiple antigens to detect specific antibodies or to screen for ANAs, respectively. The antigens are either from cell extracts or recombinant. Blood serum is incubated in the wells of the plate and is washed out. If antibodies that bind to antigen are present then they will remain after washing. A secondary anti-human antibody conjugated to an enzyme such as horseradish peroxidase is added. The enzyme reaction will produce a change in colour of the solution that is proportional to the amount of antibody bound to the antigen. There are significant differences in the detection of ANA by immunofluorescence and different ELISA kits and there is only a marginal agreement between these. A clinician must be familiar with the differences in order to evaluate the outcomes of the various assays.
Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. This enzyme phosphorylates tyrosine residues located in the C-terminal end of Src-family kinases (SFKs) including SRC, HCK, FYN, LCK, LYN and YES1.
Sources: en.wikipedia.org
Myxedema's characteristic physical sign is non-pitting edema, in contrast to pitting edema. Myxedema can also occur in the lower leg (pretibial myxedema) and behind the eyes (exophthalmos). Severe cases, requiring hospitalization can exhibit signs of hypothermia, hypoglycemia, hypotension, respiratory depression, and coma.
Conventional radiotherapy, limited to the involved area of tumour, is the mainstay of treatment for DIPG. The standard treatment is a total radiation dosage ranging from 5400 to 6000 cGy, administered in daily fractions of 180 to 200 cGy (5 days/week over 6 weeks). Hyperfractionated (twice-daily) radiotherapy was used previously to deliver higher radiation dosages, but did not lead to improved survival in clinical trials. Hyperfractionated radiotherapy is no longer commonly used due to lack of clinical support showing improved survival rates, the discomfort of two radiotherapy sessions a day, and an increased risk in damaging healthy organs due to higher dosages. Radiosurgery (e.g., gamma knife or cyberknife) has a role in the treatment of DIPG and may be considered in selected cases.
== Awards == "Outstanding Achievement in Original Music Composition" - "Portal 2" - Academy of Interactive Arts and Sciences - (2012) "Best Audio" - "Portal 2" - Game Developers Choice Award - (2012) "Best Interactive Score" - "Portal 2" - Game Audio Network Guild - (2012) "Best Dialog" - "Portal 2" - Game Audio Network Guild - (2012) "Best Original Vocal Song - Pop" - "Portal 2" - Game Audio Network Guild - (2012) "Best Game Music of 2011" - "Portal 2" - Kotaku - (2012) "Best Soundtrack (Nomination)" - "Portal 2" - X-Play - (2011) "Best Sound Design (Nomination)" - "Portal 2" - X-Play - (2011) "Outstanding Creative Achievement / Interactive Entertainment Sound Production (Nomination)" - "Portal 2" - TEC Awards - (2012) "Best Original Score (Nomination)" - "Portal 2" - Spike TV Video Game Awards - (2012) "Audio of the Year (Nomination)" - "Portal 2" - Game Audio Network Guild - (2012) "Sound Design of the Year (Nomination)" - "Portal 2" - Game Audio Network Guild - (2012) "Best Cinematic / Cut Scene Sound (Nomination)" - "Left 4 Dead 2" - Game Audio Network Guild - (2010) "Best Use of Multi-Channel Surround in a Game (Nomination)" - "Left 4 Dead 2" - Game Audio Network Guild - (2010) "Best Use of Sound" - "Left 4 Dead" - What If Gaming - (2008)
== Research == Beyond acute promyelocytic leukemia (APL), research is exploring arsenic trioxide’s antitumor effects in solid tumors such as glioma, where it induces cancer cell death by regulating apoptosis and autophagy, promoting oxidative stress within tumor cells, and inhibiting tumor stem cells.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.